TrianglePembrolizumab (NCT06353997)
Pembrolizumab trial for Triple Negative Breast Cancer (NCT06353997). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated stage II or III triple-negative breast cancer, including ER/PR-low tumors up to 10%, and at least 1% stromal tumor-infiltrating lymphocytes.
The idea: INBRX-106 activates OX40 on immune T cells. It joins intravenous pembrolizumab every three weeks as an initial treatment before planned standard therapy. Ultrasounds measure tumor shrinkage after two cycles. Serial biopsies and blood samples are required.
This phase 2 study plans 12 patients. Providence’s David Page leads it; three US sites are recruiting in Portland and Los Angeles.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.